About: Raloxifene Hydrochloride     Goto   Sponge   Distinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Raloxifene Hydrochloride
rdfs:subClassOf
Has_Free_Acid_Or_Base_Form
Concept_In_Subset
Semantic_Type
  • Organic Chemical
  • Pharmacologic Substance
Preferred_Name
  • Raloxifene Hydrochloride
NSC_Code
  • 706725
UMLS_CUI
  • C0618111
CAS_Registry
  • 82640-04-8
Accepted_Therapeutic_Use_For
  • Breast cancer prevention
FDA_UNII_Code
  • 4F86W47BR6
Contributing_Source
  • FDA
ALT_DEFINITION
  • A drug used to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk of the disease or who have osteoporosis. It is also used to prevent and treat osteoporosis in postmenopausal women. It is also being studied in the prevention of breast cancer in certain premenopausal women and in the prevention and treatment of other conditions. Evista blocks the effects of the hormone estrogen in the breast and increases the amount of calcium in bone. It is a type of selective estrogen receptor modulator (SERM).NCI-GLOSS
Chemical_Formula
  • C28H27NO4S.HCl
Legacy_Concept_Name
  • Raloxifene_Hydrochloride
CHEBI_ID
  • CHEBI:50740
FULL_SYN
  • raloxifene hydrochloridePTNCI-GLOSSCDR0000572250
  • Keoxifene HydrochlorideSYNCI
  • Raloxifene HydrochloridePTNCI
  • Raloxifene HClSYNCI
  • EvistaSYDTPNSC0706725
  • EvistaPTNCI-GLOSSCDR0000572252
  • RALOXIFENE HYDROCHLORIDEPTFDA4F86W47BR6
  • 6-Hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone HydrochlorideSNNCI
  • EvistaBRNCI
  • Raloxifene.HClPTDCP30622
  • OptrumaFBNCI
  • LY-156758CNNCI
  • Raloxifene hydrochlorideSYDTPNSC0706725
DEFINITION
  • The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.NCI
code
  • C1762
sameAs
http://linked.open...y/mesh/hasConcept
is Has_Salt_Form of
is sameAs of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software